bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-14 07:26 |
bioMérieux fait évoluer sa gouvernance : Alexandre Mérieux devient Président E…
|
French | PDF • 228.9 KB | ||
| 2023-06-05 11:33 |
Mai 2023 - Déclaration sur le nombre d'actions composant le capital social et s…
|
French | PDF • 105.3 KB | ||
| 2023-05-23 11:35 |
AG 2023 - Descriptif programme rachat d'actions
|
French | PDF • 124.0 KB | ||
| 2023-05-09 18:05 |
bioMérieux receives US FDA CLIA-waiver for the BIOFIRE® SPOTFIRE® Respiratory (…
|
English | PDF • 224.6 KB | ||
| 2023-05-09 18:05 |
bioMérieux obtient la dérogation CLIA* de la Food and Drug Administration (FDA)…
|
French | PDF • 229.2 KB | ||
| 2023-04-27 07:02 |
bioMérieux – First-Quarter 2023 Business Review
|
English | PDF • 226.3 KB | ||
| 2023-04-27 07:02 |
bioMérieux – Information financière du 1er trimestre 2023
|
French | PDF • 247.7 KB | ||
| 2023-04-14 18:01 |
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement …
|
English | PDF • 253.3 KB | ||
| 2023-04-14 18:01 |
Oxford Nanopore et bioMérieux signent un partenariat stratégique pour développe…
|
French | PDF • 260.1 KB | ||
| 2023-04-13 18:31 |
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respirat…
|
English | PDF • 223.4 KB | ||
| 2023-04-13 18:31 |
bioMérieux obtient l’accréditation 510(k) de la Food and Drug Administration (F…
|
French | PDF • 228.7 KB | ||
| 2023-04-07 08:08 |
Mars 2023 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 105.9 KB | ||
| 2023-04-07 07:01 |
SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, submitted to U…
|
English | PDF • 212.5 KB | ||
| 2023-04-07 07:01 |
Demande d’accréditation FDA 510(k) déposée pour le système d’antibiogramme rapi…
|
French | PDF • 234.2 KB | ||
| 2023-04-05 07:01 |
bioMérieux launches BIOFIRE® FIREWORKS™ a cutting-edge, data-driven software so…
|
English | PDF • 223.5 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
